{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.83","value":"-0.5"},{"groupId":"OG001","spread":"1.76","value":"-0.6"}]}],"title":"Week 1, n=230, 443"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.95","value":"-0.7"},{"groupId":"OG001","spread":"1.87","value":"-0.7"}]}],"title":"Week 2, n=227, 439"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.16","value":"-0.8"},{"groupId":"OG001","spread":"2.39","value":"-1.0"}]}],"title":"Week 4, n=218, 430"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.30","value":"-1.0"},{"groupId":"OG001","spread":"2.33","value":"-1.2"}]}],"title":"Week 6, n=198, 421"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.63","value":"-1.2"},{"groupId":"OG001","spread":"2.68","value":"-1.7"}]}],"title":"Week 8, n=191, 416"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.27","value":"-1.4"},{"groupId":"OG001","spread":"3.15","value":"-2.3"}]}],"title":"Week 12, n=165, 404"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.15","value":"-1.8"},{"groupId":"OG001","spread":"3.19","value":"-2.8"}]}],"title":"Week 16, n=139, 377"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.74","value":"-2.0"},{"groupId":"OG001","spread":"3.62","value":"-3.3"}]}],"title":"Week 20, n=135, 364"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.59","value":"-1.7"},{"groupId":"OG001","spread":"3.88","value":"-4.1"}]}],"title":"Week 24, n=88, 249"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.79","value":"-2.5"},{"groupId":"OG001","spread":"3.96","value":"-4.4"}]}],"title":"Week 28, n=74, 202"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.70","value":"-1.8"},{"groupId":"OG001","spread":"4.01","value":"-4.2"}]}],"title":"Week 32, n=69, 184"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.81","value":"-1.9"},{"groupId":"OG001","spread":"4.07","value":"-4.4"}]}],"title":"Week 36, n=68, 175"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.10","value":"-1.8"},{"groupId":"OG001","spread":"4.30","value":"-4.5"}]}],"title":"Week 40, n=64, 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.40","value":"-2.0"},{"groupId":"OG001","spread":"4.35","value":"-4.7"}]}],"title":"Week 44, n=65, 166"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.88","value":"-2.0"},{"groupId":"OG001","spread":"4.65","value":"-4.2"}]}],"title":"End of Treatment, n=214, 419"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.95","value":"-2.0"},{"groupId":"OG001","spread":"4.68","value":"-3.7"}]}],"title":"4-week FU, n=204, 404"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.51","value":"-1.4"},{"groupId":"OG001","spread":"5.07","value":"-2.9"}]}],"title":"12-week FU, n=198, 401"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.32","value":"-0.7"},{"groupId":"OG001","spread":"5.14","value":"-1.8"}]}],"title":"24-week FU, n=197, 393"}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"description":"The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)","title":"Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"Kilograms (kg)"}